Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | DHODH | Q02127 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.60 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.60 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14414533 | 1.00 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDHTTPOLB | |
| Hydrochloric Acid SCHEMBL5183067 | 0.99 | ALDH1A1 (0.72) | ALDH1A1TSHRHPGDHTTPOLB | |
| SCHEMBL2463232 | 0.91 | ALDH1A1 (0.61) | ALDH1A1TSHRHPGDHTTPOLB | |
| SCHEMBL22756633 | 0.90 | ALDH1A1 (0.72) | ALDH1A1TSHRHPGDHTTPOLB | |
| Hydrochloric Acid SCHEMBL5969973 | 0.90 | ALDH1A1 (0.59) | ALDH1A1TSHRHPGDHTTPOLB | |
| Hydrochloric Acid SCHEMBL5970478 | 0.90 | ALDH1A1 (0.59) | ALDH1A1TSHRHPGDHTTPOLB | |
| SCHEMBL3151520 | 0.86 | ALDH1A1 (0.67) | ALDH1A1TSHRHPGDHTTDHODH | |
| SCHEMBL4009579 | 0.85 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDHTTPOLB | |
| SCHEMBL20990440 | 0.85 | ALDH1A1 (0.74) | ALDH1A1TSHRHPGDHTTDHODH | |
| SCHEMBL53323 | 0.85 | ALDH1A1 (1.00) | ALDH1A1TSHRHPGDHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678121-A4 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1678121-A2 | TAO KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005040355-A2 | TAO KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | claimed |
| EP-3180003-B1 | PKC-EPSILON INHIBITORS | UNIV CALIFORNIA (US) | 2022-01-12 | — | — | EP | disclosed |
| EP-2457896-A1 | Tripeptides as caspase modulators | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2457895-A1 | Tetrapeptide analogs | Idun Pharmaceuticals, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20100190688-A1 | Tetrapeptide analogs | IDUN PHARMACEUTICALS, INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1773348-A4 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | EXELIXIS, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| EP-1773348-A2 | TETRAPEPTIDE ANALOGS | Idun Pharmaceuticals, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006017295-A2 | TETRAPEPTIDE ANALOGS | IDUN PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | WO | disclosed |
| EP-1140852-A1 | 1,2,3,4-TETRAHYDRONAPHTHALENES AND THEIR PHARAMACEUTICAL USE | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000035882-A1 | 1,2,3,4-TETRAHYDRONAPHTHALENES AND THEIR PHARMACEUTICAL USE | ASTRAZENECA AB (SE) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190688-A1 | Tetrapeptide analogs | TP53, PCNA, HRAS | ALDH1A1 4425/4885TSHR 3117/4885HPGD 1747/4885 |
| US-20070208166-A1 | Tao Kinase Modulators And Method Of Use | TAOK1, TAOK3, MAP3K6 | ALDH1A1 4424/4885TSHR 2539/4885HPGD 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.